Table 3.
Adverse Events During the 12-Month Follow-up
| Intervention, N=156 n (%) |
Control, N=156 n (%) |
|
|---|---|---|
| Adverse events potentially related to hypertension, antihypertensive treatment and/or intervention | ||
| Syncope due to hypotension | 2 (1.28%) | 1 (0.64%) |
| Hypotension | 3 (1.92%) | 0 (0.00%) |
| Swelling of legs and/or ankles | 0 (0.00%) | 3 (1.92%) |
| Heart arrhythmia | 1 (0.64%) | 1 (0.64%) |
| Hospitalization due to hydro electrolytic disorder potentially associated with ARBs treatment | 1 (0.64%) | 0 (0.00%) |
| Heart palpitations | 1 (0.64%) | 0 (0.00%) |
| Transient ischemic attack | 0 (0.00%) | 1 (0.64%) |
| Serious adverse eventsa | ||
| Breast cancer | 2 (1.28%) | 1 (0.64%) |
| Melanoma | 0 (0.00%) | 1 (0.64%) |
| Prostate cancer | 0 (0.00%) | 1 (0.64%) |
| Paroximal supraventricular tachycardiab,c | 0 (0.00%) | 1 (0.64%) |
| Acute pyelonephritisb | 1 (0.64%) | 0 (0.00%) |
| Hospitalization due to hydro electrolytic disorder potentially associated with ARBs treatment | 1 (0.64%) | 0 (0.00%) |
aDefined as any clinical event requiring hospitalization, endangering the patient’s life, or having an otherwise substantial impact on the patient’s health, as determined by the researcher. These may be related or unrelated to hypertension, antihypertensive treatment, and/or intervention
bAdverse event that required hospitalization. ARBs, angiotensin receptor blockers
cThis adverse event is also included under the category “Adverse events potentially related to hypertension, antihypertensive treatment and/or intervention”